Author: McCreary, Erin K; Pogue, Jason M
Title: Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options Document date: 2020_3_23
ID: j0i9ozsz_39
Snippet: Interferons (α, β) may stimulate innate antiviral responses and are expected to have in vitro activity against SARS-CoV-2, given the previously described activity demonstrated against MERS-CoV (EC 50 175 IU/mL). However, toxicities are substantial including severe cytopenias, hepatotoxicity (including fatality), neuropsychiatric events, and risk of developing fatal or life-threatening ischemia or infection, particularly when combined with ribav.....
Document: Interferons (α, β) may stimulate innate antiviral responses and are expected to have in vitro activity against SARS-CoV-2, given the previously described activity demonstrated against MERS-CoV (EC 50 175 IU/mL). However, toxicities are substantial including severe cytopenias, hepatotoxicity (including fatality), neuropsychiatric events, and risk of developing fatal or life-threatening ischemia or infection, particularly when combined with ribavirin. This combination was not associated with improved mortality or enhanced viral clearance in a retrospective analysis of patients infected with MERS-CoV who were initiated on combination therapy within 1-3 days of ICU admission [57] . Despite the limited to poor data, Chinese guidelines recommend ribavirin 500 mg IV 2-3 times daily in combination with LPV/r or inhaled interferon-α (5 million units nebulized twice daily) as one of the "standard treatment" options for COVID-19. Various combinations of ribavirin, interferon, and other antiviral agents are currently being studied in several clinical trials.
Search related documents:
Co phrase search for related documents- antiviral agent and clinical trial study: 1
- antiviral agent and combination therapy: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral agent and SARS vitro activity: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral agent and treatment option: 1, 2, 3
- antiviral agent and viral clearance: 1, 2, 3, 4, 5, 6
- antiviral agent and vitro activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- antiviral response and clinical trial: 1, 2, 3, 4, 5, 6
- antiviral response and combination therapy: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral response and ICU admission: 1, 2
- antiviral response and SARS vitro activity: 1
- antiviral response and viral clearance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
- antiviral response and vitro activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- antiviral response innate and clinical trial: 1
- antiviral response innate and combination therapy: 1
- antiviral response innate and ICU admission: 1
- antiviral response innate and viral clearance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- antiviral response innate and vitro activity: 1
- chinese guideline and clinical trial: 1
- clinical trial and combination therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
Co phrase search for related documents, hyperlinks ordered by date